Spots Global Cancer Trial Database for Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
Official Title: A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer
Study ID: NCT05796089
Conditions
Study Description
Brief Summary: This is a prospective, multi-centre, single arm, phase 2, open label clinical trial of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) suitable for first-line platinum-based chemotherapy. The aim of the trial is to assess safety, feasibility and describe efficacy of the addition of concurrent thoracic radiotherapy to usual treatment of chemotherapy and immunotherapy (durvalumab) in patients with ES-SCLC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Westmead Hospital, Sydney, New South Wales, Australia
Blacktown Hospital, Sydney, New South Wales, Australia
Liverpool Hospital, Sydney, New South Wales, Australia
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Princess Alexandra Hospital, Brisbane, Queensland, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
St. Vincent's Hospital, Melbourne, Victoria, Australia
Austin Health, Melbourne, Victoria, Australia
Contact Details
Name: Eric Hau
Affiliation: Westmead/Blacktown Hospital
Role: STUDY_CHAIR
Name: Sagun Parakh
Affiliation: Austin Health
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
